Literature DB >> 27470216

The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: Implications for the future.

Dirk Rades1, Daniel Seidl2, Stefan Janssen3, Barbara Wollenberg4, Samer G Hakim5, Steven E Schild6.   

Abstract

This study investigated the prognostic implications of pre-radiotherapy hemoglobin levels after microscopically complete (R0) resection of locally advanced squamous cell carcinoma of the head-and-neck (SCCHN) and reviewed the question "should anemia be corrected?". A total of 225 patients receiving R0-resection and postoperative irradiation were retrospectively evaluated. Pre-radiotherapy hemoglobin levels (<12 vs. ≥12 g/dl) plus eight factors (T-/N-category, AJCC-stage, performance score, gender, age, tumor site, and histologic grading) were analyzed for locoregional control and survival. Hemoglobin levels of <12 and ≥12 g/dl were associated with 3-year locoregional control rates of 67% and 84%, respectively, and 5-year locoregional control rates of 63% and 74%, respectively (p = 0.029). On multivariate analysis of locoregional control, hemoglobin levels achieved significance (hazard ratio [HR] 1.97; 95%-confidence interval [95%-CI] 1.02-3.81; p = 0.043). Hemoglobin levels of <12 and ≥12 g/dl were associated with 3-year survival rates of 55% and 87%, respectively, and 5-year survival rates of 25% and 71%, respectively (p < 0.001). On multivariate analysis of survival, hemoglobin levels were significant (HR 2.91; 95%-CI 1.67-5.22; p < 0.001). Thus, pre-radiotherapy hemoglobin is an independent predictor for outcomes after R0-resection of SCCHN. Levels <12 g/dl were associated with worse outcomes than ≥12 g/dl. Tumor cell oxygenation and correction of anemia appear important also after R0-resection.
Copyright © 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hemoglobin levels; Locally advanced SCCHN; Locoregional control; R0-resection; Survival

Mesh:

Substances:

Year:  2016        PMID: 27470216     DOI: 10.1016/j.jcms.2016.07.003

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  1 in total

1.  Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy.

Authors:  Lucas Maahs; Ahmed I Ghanem; Radhika Gutta; Amy Tang; Swarn Arya; Zaid Al Saheli; Haythem Ali; Steven Chang; Samantha Tam; Vivian Wu; Farzan Siddiqui; Jawad Sheqwara
Journal:  BMC Cancer       Date:  2022-06-07       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.